Inhibitory effects of Zingiber officinale roscoe derived components on aldose reductase activity in vitro and in vivo

Journal of Agricultural and Food Chemistry

Volumn 54, Issue 18, 2006, Pages 6640-6644

  Kato, Atsushi ^a   Higuchi, Yasuko ^a   Goto, Hirozo ^b   Kizu, Haruhisa ^c   Okamoto, Tadashi ^d   Asano, Naoki ^c,d   Hollinshead, Jackie ^e   Nash, Robert J ^e   Adachi, Isao ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

^d KOBE GAKUIN UNIVERSITY   (Japan)

^e ABERYSTWYTH UNIVERSITY   (United Kingdom)

Author keywords

Aldose reductase inhibitor; Diabetes; Erythrocyte; Galactosemia; Ginger; Sorbitol; Zingiber officinale

Indexed keywords

2 (4 HYDROXY 3 METHOXYPHENYL)ETHANOIC ACID; 2 (4 HYDROXY 3 METHOXYPHENYL)ETHANOL; 2-(4-HYDROXY-3-METHOXYPHENYL)ETHANOIC ACID; 2-(4-HYDROXY-3-METHOXYPHENYL)ETHANOL; ALDEHYDE REDUCTASE; BENZENE DERIVATIVE; CARBOXYLIC ACID; DRUG DERIVATIVE; ENZYME INHIBITOR; GALACTITOL; PHENETHYL ALCOHOL; RECOMBINANT PROTEIN; SORBITOL;

ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ERYTHROCYTE; GINGER; HUMAN; ISOLATION AND PURIFICATION; LENS; MALE; METABOLISM; RAT; WISTAR RAT;

ALDEHYDE REDUCTASE; ANIMALS; BENZENE DERIVATIVES; CARBOXYLIC ACIDS; ENZYME INHIBITORS; ERYTHROCYTES; GALACTITOL; GINGER; HUMANS; LENS, CRYSTALLINE; MALE; PHENYLETHYL ALCOHOL; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SORBITOL;

ZINGIBER OFFICINALE;

EID: 33748915431     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf061599a     Document Type: Article

References (42)

1. Akhani, S. P.; Vishwakarma, S. L.; Goyal, R. K. Anti-diabetic activity of Zingiber officinale in streptozotocin-induced type I diabetic rats. J. Pharm. Pharmacol. 2004, 56, 101-105.
2. Kadnur, S. V.; Goyal, R. K. Beneficial effects of Zingiber officinale Roscoe on fructose induced hyperlipidemia and hyperinsulinemia in rats. Indian J. Exp. Biol. 2005, 43, 1161-1164.
3. Winegrad, A. I. Does a common mechanism induce the diverse complications of diseases? Diabetes 1987, 36, 396-405.
4. Kador, P. J.; Kinoshita, J. H.; Sharpless, N. E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem. 1985, 28, 841-849.
5. Nishimura-Yabe, C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. 1998, 50, 21-34.
6. Carper, D. A.; Nishimura, C.; Shinohara, T.; Dietzchold, B.; Wistow, G.; Craft, C.; Kandor, P.; Kinoshita, J. H.; Kandor, P.; Kinoshita, J. H. Aldose reductase and p-crystalline belong to the same protein superfamily as aldehyde reductase. FEBS Lett. 1987, 220, 209-213.
7. Carper, D. A.; Wistow, G.; Nishimura, C.; Graham, C.; Watanabe, K.; Fujii, Y.; Hayashi, H.; Hayashi, O. A superfamily of NADPH-dependent reductases in eukaryotes and prokaryotes. Exp. Eye Res. 1989, 49, 377-388.
8. Robinson, W. G.; Kador, J. P.; Kinoshita, J. H. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science 1983, 221, 1177-1178.
9. Frank, R. N.; Keirn, R. J.; Kennedy, A.; Frank, K. W. Galactose-induced retinal capillary basement membrane thickening: prevention by sorbinil. Invest. Ophthalmol. Visual Sci. 1983, 24, 1519-1524.
10. Robinson, W. G.; Nagata, M.; Laver, N.; Hohman, T. C.; Kinoshita, J. H. Diabetic-like retinopathy in rat prevented with an aldose reductase inhibitor. Invest. Ophthalmol. Visual Sci. 1989, 30, 2285-2292.
11. Engerman, R. L. Pathogenesis of diabetic retinopathy. Diabetes 1989, 38, 1203-1206.
12. Young, R. J.; Ewing, D. J.; Clarke, B. F. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983, 32, 938-942.
13. Dunlop, M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int. 2000, 58 (Suppl. 77), S-3-S-12.
14. Kaul, C. L.; Ramarao, P. The role of aldose reductase inhibitors in diabetic complications: recent trends. Methods Find Exp. Clin. Pharmacol. 2001, 23, 465-475.
15. Kirchain, W. R.; Rendell, M. S. Aldose reductase inhibitors. Pharmacotherapy 1990, 10, 326-336.
16. Larson, E. R.; Lipinski, C. A.; Sarges, R. Medicinal chemistry of aldose reductase inhibitors. Med. Res. Rev. 1988, 8, 159-186.
17. Sarges, R.; Schnur, R. C.; Belletire, J. L.; Peterson, M. J. Spirohydantoin aldose reductase inhibitors. J. Med. Chem. 1988, 31, 230-243.
18. Hotta, N.; Kakuta, H.; Ando, F.; Sakumoto, N. Current progress in clinical trials of aldose reductase inhibitors in Japan. Exp. Eye Res. 1990, 50, 625-628.
19. Malamas, M. S.; Hohman, T. C.; Millen, J. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2- fluorophenyl)methyl]-6-fluorospirono-[isoquionoline-4(1H),3′-pyrrolidine] -1,2′,3,5′(2H)-tetrone and congeners. 1. J. Med. Chem. 1994, 37, 2043-2058.
20. Pitts, N. E.; Vreeland, F.; Shaw, G. L.; Peterson, M. J.; Mehta, D. J.; Collier, J.; Gundersen, K. Clinical experience with sorbinil - an aldose reductase inhibitor. Metabolism 1986, 35, 96-100.
21. Spielberg, S. P.; Shear, N. H.; Cannon, M.; Hutson, N.; Gunderson, K. In vitro assessment of a hypersensitivity syndrome associated with sorbinil. Ann. Intern. Med. 1991, 114, 720-724.
22. Sarges, R. Aldose reductase inhibitors: structure-activity relationships and therapeutic potential. Advances in Drug Research; Academic Press: San Diego, 1989; Vol. 18, pp 139-175.
23. Humber, L. G. The medicinal chemistry of aldose reductase inhibitors. Progress in Medicinal Chemistry; Elsevier Science Publishers: New York, 1987; Vol. 24, pp 299-343.
24. Kawanishi, K.; Ueda, H.; Moriyasu, M. Aldose reductase inhibitors from nature. Curr. Med. Chem. 2003, 10, 1353-1374.
25. Yoshikawa, M.; Yamaguchi, S.; Kunimi, K.; Matsuda, H.; Okuno, Y.; Yamahara, J.; Murakami, N. Stomachic principles in ginger. III. An anti-ulcer principle, 6-gingesulfonic acid, and three monoacyldigalactosylglycerols, gingerglycolipids A, B, and C, from Zingiberis rhizoma originating. Chem. Pharm. Bull. 1994, 42, 1226-1230.
26. Kikuchi, F.; Iwanami, S.; Shibuya, M.; Hanaoka, F.; Sankawa, U. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem. Pharm. Bull. 1992, 40, 387-391.
27. Kikuzaki, H.; Usuguchi, J.; Nakatani, N. Constituents of zingiberaceae. I. Diarrylheptanoids from rhizomes of ginger (Zingiber officinale Roscoe). Chem. Pharm. Bull. 1991, 39, 120-122.
28. Endo, K.; Kanno, E.; Oshima, Y. Structures of antifungal diarylheptenones, gingerenones A, B, C and isogingerenone B, isolated from the rhizomes of Zingiber officinale. Phytochemistry 1990, 29, 797-799.
29. Cappiello, M.; Voltarelli, M.; Giannessi, M.; Cecconi, I.; Camici, G.; Manao, G.; Corso, A.; Mura, U. Glutathione dependent modification of bovine lends aldose reductase. Exp. Eye Res. 1994, 58, 491-501.
30. Malone, J. I.; Knox, G.; Benford, S.; Tedesco, T. A. Red cell sorbitol: an inhibitor of diabetic control. Diabetes 1980, 29, 861-864.
31. Haraguchi, H.; Ohmi, I.; Fukuda, A.; Tamura, Y.; Mizutani, K.; Tanaka, O.; Chou, W. H. Inhibition aldose reductase and sorbitol accumulation by astilbin and taxifolin dihydroflavonols in Engelhardtia chrysolepis. Biosci., Biotechnol., Biochem. 1997, 61, 651-654.
32. Clements, R. S., Jr.; Morrison, A. D.; Winegrad, A. I. Polyol pathway in aorta: regulation by hormones. Science 1969, 166, 1007-1008.
33. Arola, H.; Sillanaukee, P.; Aline, E.; Koivula, T.; Isokoshi, M. Galactitol is not cause of senile cataract. Graefe's Arch. Clin. Exp. Opthalnol. 1992, 230, 240-242.
34. Bentley, B.; Sweeley, C. C.; Makita, M.; Wells, W. W. Gas chromatography of sugars and other polyhydroxy compounds. Biochem. Biophys. Res. Commun. 1963, 11, 14-18.
35. Manius, G.; Mahn, E. P.; Venturella, V. S.; Senkowski, B. Z. GLC determination of sorbitol and mannitol in aqueous solutions J. Pharm. Sci. 1972, 61, 1831-1835.
36. Okuda, J.; Miwa, I.; Inagaki, K.; Horie, T.; Nakayama, M. Inhibition of aldose reductases from rat and bovine lenses by flavonoids. Biochem. Pharmacol. 1982, 31, 3807-3822.
37. Hamada, Y.; Kitoh, R.; Raskin, P. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes 1991, 40, 1233-1240.
38. Malone, J. I.; Leavengood, H.; Peterson, M. J.; O'Brien, M. M.; Page, M. G.; Aldinger, C. E. Red blood cell sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulin-dependent diabetic subjects. Diabetes 1984, 33, 45-49.
39. Hotta, N.; Kakuta, H.; Fukasawa, H.; Kimura, M.; Koh, N.; Iida, M.; Terashima, H.; Morimura, T.; Sakumoto, N. Effect of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats. Diabetologia 1985, 28, 176-180.
40. Kinoshita, J. H. Mechanisms initiating cataract formation. Invest. Ophthalmol. 1974, 13, 713-724.
41. Kador, P. F.; Inoue, J.; Secchi, E. F.; Lizak, M. J.; Rodriguez, L.; Mori, K.; Greentree, W.; Blessing, K.; Lackner, P. A.; Sato, S. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats. Exp. Eye Res. 1998, 67, 203-208.
42. Stribling, D. Clinical trials with aldose reductase inhibitors. Exp. Eye Res. 1990, 50, 621-624.